DNA Immunization

Genetically Modified Dendritic Cells Elicit Antitumor Responses

Published in Gene Therapy Weekly, April 6th, 1998

Autologous human monocyte-derived dendritic cells (DCs) which have been genetically modified to express melanoma antigens elicited antitumor responses in vitro. The effects were enhanced by cotransfection of the cytokine genes for interleukin-12 (IL-12) and interferon-(alpha) (IFN-(alpha)).

An attractive alternative to protein- or peptide-based immunization approaches involves the use of DCs in a DNA-based strategy. Thomas Tuting and a research team from several institutions evaluated the feasibility of DNA vaccination for the induction of cytotoxic T cell (CTL) reactivity to five different melanoma antigens (Ags) in vitro ("Autologous Human Monocyte-Derived Dendritic...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (1998-04-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry